"Remission Induction" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Therapeutic act or process that initiates a response to a complete or partial remission level.
| Descriptor ID |
D012074
|
| MeSH Number(s) |
E02.860
|
| Concept/Terms |
Remission Induction- Remission Induction
- Induction, Remission
- Inductions, Remission
- Induction of Remission
- Remission Inductions
|
Below are MeSH descriptors whose meaning is more general than "Remission Induction".
Below are MeSH descriptors whose meaning is more specific than "Remission Induction".
This graph shows the total number of publications written about "Remission Induction" by people in this website by year, and whether "Remission Induction" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 17 | 17 |
| 1996 | 0 | 10 | 10 |
| 1997 | 0 | 11 | 11 |
| 1998 | 1 | 8 | 9 |
| 1999 | 0 | 7 | 7 |
| 2000 | 0 | 17 | 17 |
| 2001 | 0 | 8 | 8 |
| 2002 | 0 | 11 | 11 |
| 2003 | 0 | 14 | 14 |
| 2004 | 0 | 15 | 15 |
| 2005 | 1 | 13 | 14 |
| 2006 | 0 | 11 | 11 |
| 2007 | 1 | 16 | 17 |
| 2008 | 0 | 18 | 18 |
| 2009 | 0 | 16 | 16 |
| 2010 | 0 | 12 | 12 |
| 2011 | 1 | 21 | 22 |
| 2012 | 1 | 14 | 15 |
| 2013 | 0 | 15 | 15 |
| 2014 | 0 | 18 | 18 |
| 2015 | 0 | 16 | 16 |
| 2016 | 0 | 16 | 16 |
| 2017 | 0 | 13 | 13 |
| 2018 | 1 | 19 | 20 |
| 2019 | 2 | 17 | 19 |
| 2020 | 3 | 16 | 19 |
| 2021 | 0 | 13 | 13 |
| 2022 | 0 | 8 | 8 |
| 2023 | 0 | 18 | 18 |
| 2024 | 6 | 9 | 15 |
| 2025 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Remission Induction" by people in Profiles.
-
Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies. J Crohns Colitis. 2025 Jan 11; 19(1).
-
Tamuzimod in patients with moderately-to-severely active ulcerative colitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trial. Lancet Gastroenterol Hepatol. 2025 Mar; 10(3):210-221.
-
Real-World Effectiveness of Ustekinumab in Ulcerative Colitis in a United States Multicenter Cohort Consortium. Inflamm Bowel Dis. 2025 01 06; 31(1):131-139.
-
Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2025 Feb; 10(2):138-153.
-
Single-center Experience With Upadacitinib for Adolescents With Refractory Inflammatory Bowel Disease. Inflamm Bowel Dis. 2024 11 04; 30(11):2057-2063.
-
Adaptive Steroid Tapering Impedes Corticosteroid-free Remissions Compared with Forced Tapering in Clinical Trials of Ulcerative Colitis. J Crohns Colitis. 2024 Nov 04; 18(11):1863-1869.
-
Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis. N Engl J Med. 2024 Sep 26; 391(12):1119-1129.
-
Early Intestinal Ultrasound Response to Biologic Therapy Predicts Endoscopic Remission in Children with Ileal Crohn's Disease: Results from the Prospective Super Sonic Study. J Crohns Colitis. 2024 Aug 06; 18(7):1002-1011.
-
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults. N Engl J Med. 2024 Jul 25; 391(4):320-333.
-
Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission. Blood Cancer J. 2024 07 08; 14(1):108.